[Review of recent research on hepatitis C therapy for 54th annual meeting of the American association for the study of liver diseases].
Wei
Lai
L
Hepatology Institute, Peking University People's Hospital, Beijing 100044, China.
D002219:Carbamates / Q000627:therapeutic use*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D047028:Macrocyclic Compounds; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D011804:Quinolines; D012324:RNA-Dependent RNA Polymerase / Q000037:antagonists & inhibitors; D012709:Serum Albumin / Q000627:therapeutic use; D000075462:Serum Albumin, Human; D013844:Thiazoles / Q000627:therapeutic use*; D014761:Viral Hepatitis Vaccines / Q000627:therapeutic use
C479555:BILN 2061; D002219:Carbamates; D016898:Interferon-alpha; D047028:Macrocyclic Compounds; D016376:Oligonucleotides, Antisense; D011804:Quinolines; D012709:Serum Albumin; D013844:Thiazoles; D014761:Viral Hepatitis Vaccines; C473631:albuferon; D007372:Interferons; D012324:RNA-Dependent RNA Polymerase; D000075462:Serum Albumin, Human